No Data
There's No Escaping Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Muted Revenues Despite A 38% Share Price Rise
Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
Strong Week for Enanta Pharmaceuticals (NASDAQ:ENTA) Shareholders Doesn't Alleviate Pain of Three-year Loss
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20
